Vertex submits CF drug NDA, but no investor Incivek-like excitement
This article was originally published in Scrip
Vertex Pharmaceuticals took a step closer to being the first company on the US market with a treatment targeting the underlying cause of cystic fibrosis (CF) by submitting its new drug application (NDA) to the US FDA for Kalydeco (ivacaftor), formerly known as VX-770, an oral drug that targets the defective protein that causes CF, known as CF transmembrane conductance regulator (CFTR), a ATP-binding cassette transporter protein.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.